Hyppigheden af klinisk signifikante infektioner, af hvilke nogle var fatale, var 0, 05 pr. patientår hos patienter behandlet med MabThera.
The incidence of clinically significant infection, some of which were fatal, was 0.05 per patient year in MabThera treated patients.